交易 Rhythm Pharma - RYTM CFD
加入收藏夹- 概括
- 曆史數據
- 活動
- 收入報表
- 資産負債表
- 現金流
价差 | 0.13 | ||||||||
多头隔夜费
多头隔夜费
前往平台 | -0.026179% | ||||||||
空头隔夜费
空头隔夜费
前往平台 | 0.003957% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 5% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Rhythm Pharmaceuticals Inc ESG Risk Ratings
“C”分數表示在公開報告重大 ESG 數據方面令人滿意的相對 ESG 表現和適度的透明度。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 關閉 | 更改 | 變化 (%) | 打開 | 高 | 低 |
---|---|---|---|---|---|---|
Apr 18, 2024 | 38.00 | 0.27 | 0.72% | 37.73 | 38.71 | 37.52 |
Apr 17, 2024 | 38.32 | -0.15 | -0.39% | 38.47 | 38.69 | 38.20 |
Apr 16, 2024 | 38.45 | -0.99 | -2.51% | 39.44 | 40.03 | 38.45 |
Apr 15, 2024 | 40.04 | -0.25 | -0.62% | 40.29 | 40.91 | 39.50 |
Apr 12, 2024 | 40.26 | -1.69 | -4.03% | 41.95 | 41.95 | 39.76 |
Apr 11, 2024 | 42.46 | 1.35 | 3.28% | 41.11 | 42.54 | 40.94 |
Apr 10, 2024 | 41.02 | 0.11 | 0.27% | 40.91 | 42.34 | 40.78 |
Apr 9, 2024 | 43.54 | 1.79 | 4.29% | 41.75 | 43.57 | 40.46 |
Apr 8, 2024 | 41.67 | 0.56 | 1.36% | 41.11 | 41.84 | 40.19 |
Apr 5, 2024 | 40.50 | 1.24 | 3.16% | 39.26 | 41.35 | 39.19 |
Apr 4, 2024 | 40.04 | -0.90 | -2.20% | 40.94 | 41.86 | 39.80 |
Apr 3, 2024 | 40.82 | 1.35 | 3.42% | 39.47 | 40.88 | 39.31 |
Apr 2, 2024 | 39.94 | -1.68 | -4.04% | 41.62 | 41.93 | 39.75 |
Apr 1, 2024 | 42.58 | 0.61 | 1.45% | 41.97 | 42.68 | 41.48 |
Mar 28, 2024 | 43.20 | 0.76 | 1.79% | 42.44 | 43.54 | 41.71 |
Mar 27, 2024 | 41.74 | 1.69 | 4.22% | 40.05 | 42.23 | 39.55 |
Mar 26, 2024 | 39.42 | 0.13 | 0.33% | 39.29 | 40.81 | 38.96 |
Mar 25, 2024 | 39.51 | -0.67 | -1.67% | 40.18 | 40.84 | 39.25 |
Mar 22, 2024 | 40.46 | 0.97 | 2.46% | 39.49 | 40.70 | 39.49 |
Mar 21, 2024 | 40.53 | 0.59 | 1.48% | 39.94 | 41.74 | 39.10 |
Rhythm Pharma Events
时间(协调世界时) (UTC) | 国家 | 事件 |
---|---|---|
Tuesday, April 30, 2024 | ||
时间(协调世界时) (UTC) 12:30 | 国家 US
| 事件 Q1 2024 Rhythm Pharmaceuticals Inc Earnings Release Q1 2024 Rhythm Pharmaceuticals Inc Earnings ReleaseForecast(预报) -上一页 - |
Thursday, June 20, 2024 | ||
时间(协调世界时) (UTC) 18:00 | 国家 US
| 事件 Rhythm Pharmaceuticals Inc Annual Shareholders Meeting Rhythm Pharmaceuticals Inc Annual Shareholders MeetingForecast(预报) -上一页 - |
Tuesday, July 30, 2024 | ||
时间(协调世界时) (UTC) 12:30 | 国家 US
| 事件 Q2 2024 Rhythm Pharmaceuticals Inc Earnings Release Q2 2024 Rhythm Pharmaceuticals Inc Earnings ReleaseForecast(预报) -上一页 - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 23.638 | 3.154 | 0 | 0 | 0 |
總營業費用 | 202.795 | 173.213 | 136.575 | 146 | 78.417 |
銷售/一般/行政費用,總計 | 92.032 | 68.486 | 46.125 | 36.55 | 28.08 |
研究與開發 | 108.63 | 104.128 | 90.45 | 109.45 | 50.337 |
營業收入 | -179.157 | -170.059 | -136.575 | -146 | -78.417 |
利息收入(費用),非經營淨值 | -1.172 | 0.447 | 2.579 | 5.271 | 4.353 |
其他,淨值 | -0.79 | 100 | 0 | 0 | |
稅前淨收入 | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
稅後淨收入 | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
未計算非常項目前的淨收益 | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
淨收入 | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
Total Adjustments to Net Income | 0 | 0 | |||
普通股股東可獲收益 (不含非經常性項目) | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
普通股股東可獲收益 (含非經常性項目) | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
攤薄淨收入 | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
攤薄後加權平均股 | 52.1207 | 49.6003 | 44.1272 | 36.4225 | 31.004 |
扣除特別項目的每股攤薄盈利 | -3.47499 | -1.40346 | -3.03658 | -3.8638 | -2.38885 |
Dividends per Share - Common Stock Primary Issue | |||||
每股正常攤薄盈利 | -3.47499 | -1.40346 | -3.03658 | -3.8638 | -2.38885 |
收入 | 23.638 | 3.154 | |||
收入成本,共計 | 2.133 | 0.599 | |||
毛利 | 21.505 | 2.555 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 19.221 | 11.469 | 8.79 | 4.284 | 9.066 |
收入 | 19.221 | 11.469 | 8.79 | 4.284 | 9.066 |
收入成本,共計 | 2.236 | 1.421 | 1.028 | 0.497 | 0.378 |
毛利 | 16.985 | 10.048 | 7.762 | 3.787 | 8.688 |
總營業費用 | 65.825 | 64 | 50.893 | 43.551 | 54.162 |
銷售/一般/行政費用,總計 | 30.046 | 24.634 | 26.317 | 21.938 | 22.328 |
研究與開發 | 33.543 | 37.945 | 23.548 | 21.116 | 31.456 |
營業收入 | -46.604 | -52.531 | -42.103 | -39.267 | -45.096 |
利息收入(費用),非經營淨值 | -0.082 | 0.379 | 0.03 | -1.224 | 0.095 |
其他,淨值 | -0.017 | -0.027 | -0.42 | -0.37 | 0 |
稅前淨收入 | -46.703 | -52.179 | -42.493 | -40.861 | -45.001 |
稅後淨收入 | -46.703 | -52.179 | -42.493 | -40.861 | -45.001 |
未計算非常項目前的淨收益 | -46.703 | -52.179 | -42.493 | -40.861 | -45.001 |
淨收入 | -46.703 | -52.179 | -42.493 | -40.861 | -45.001 |
普通股股東可獲收益 (不含非經常性項目) | -46.703 | -52.179 | -42.493 | -40.861 | -45.001 |
普通股股東可獲收益 (含非經常性項目) | -46.703 | -52.179 | -42.493 | -40.861 | -45.001 |
攤薄淨收入 | -46.703 | -52.179 | -42.493 | -40.861 | -45.001 |
攤薄後加權平均股 | 56.8677 | 56.709 | 56.3455 | 51.4009 | 50.398 |
扣除特別項目的每股攤薄盈利 | -0.82126 | -0.92012 | -0.75415 | -0.79495 | -0.89291 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -0.82126 | -0.92012 | -0.75415 | -0.79495 | -0.89291 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 354.236 | 308.387 | 181.668 | 302.404 | 258.689 |
現金和短期投資 | 333.288 | 294.855 | 172.792 | 292.459 | 252.061 |
現金等價物 | 127.677 | 59.248 | 100.854 | 62.294 | 49.542 |
短期投資 | 205.611 | 235.607 | 71.938 | 230.165 | 202.519 |
預付的費用 | 4.392 | 8.404 | 5.828 | 6.438 | 5.288 |
其他流動資産,總計 | 7.415 | 4.103 | 3.048 | 3.507 | 1.34 |
總資産 | 382.481 | 329.523 | 187.073 | 308.523 | 260.21 |
物業/廠房/設備,總計 - 淨額 | 3.379 | 4.335 | 5.002 | 5.716 | 1.12 |
物業/廠房/設備,總計 - 總額 | 6.534 | 6.593 | 6.444 | 6.468 | 1.929 |
累計折舊,總計 | -3.155 | -2.258 | -1.442 | -0.752 | -0.809 |
應收票據 - 長期 | |||||
其他長期資産,總計 | 16.983 | 12.143 | 0.403 | 0.403 | 0.401 |
流動負債總額 | 39.809 | 43.427 | 17.994 | 24.417 | 13.582 |
應付賬款 | 4.797 | 5.737 | 4.9 | 10.415 | 7.64 |
預提費用 | 33.578 | 30.69 | 13.094 | 14.002 | 5.942 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 1.434 | 7 | 0 | ||
負債總額 | 118.219 | 45.372 | 20.545 | 27.503 | 13.954 |
長期債務總額 | 75.81 | 0 | 0 | 0 | 0.372 |
其他負債,總計 | 2.6 | 1.945 | 2.551 | 3.086 | |
總權益 | 264.262 | 284.151 | 166.528 | 281.02 | 246.256 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
普通股 | 0.056 | 0.05 | 0.044 | 0.044 | 0.034 |
額外實收資本 | 974.356 | 813.041 | 625.762 | 606.307 | 430.824 |
留存收益(累計赤字) | -710.058 | -528.939 | -459.327 | -325.331 | -184.602 |
總負債和股東權益 | 382.481 | 329.523 | 187.073 | 308.523 | 260.21 |
已發行普通股總數 | 56.6124 | 50.2836 | 44.2359 | 43.9967 | 34.4107 |
長期債務 | 75.81 | 0 | 0.372 | ||
其他權益,總計 | -0.092 | -0.001 | 0.049 | ||
應收賬款總額,淨額 | 6.224 | 1.025 | |||
應收賬款 - 貿易,淨額 | 6.224 | 1.025 | |||
無形資産,淨額 | 7.883 | 4.658 | |||
總庫存 | 2.917 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 329.201 | 283.878 | 317.838 | 354.236 | 361.874 |
現金和短期投資 | 299.26 | 253.602 | 294.582 | 333.288 | 347.795 |
現金等價物 | 64.593 | 115.684 | 109.661 | 127.677 | 185.087 |
短期投資 | 234.667 | 137.918 | 184.921 | 205.611 | 162.708 |
預付的費用 | 7.638 | 10.267 | 9.652 | 4.392 | 10.751 |
總資産 | 354.199 | 309.943 | 345.678 | 382.481 | 389.614 |
物業/廠房/設備,總計 - 淨額 | 2.433 | 2.763 | 3.089 | 3.379 | 3.699 |
無形資産,淨額 | 7.242 | 7.456 | 7.669 | 7.883 | 8.097 |
其他長期資産,總計 | 15.323 | 15.846 | 17.082 | 16.983 | 15.944 |
流動負債總額 | 50.144 | 46.103 | 46.029 | 39.809 | 33.098 |
應付賬款 | 3.839 | 8.383 | 13.347 | 4.797 | 4.933 |
預提費用 | 36.569 | 30.385 | 26.989 | 33.578 | 26.405 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
負債總額 | 156.725 | 127.658 | 125.915 | 118.219 | 108.419 |
長期債務總額 | 104.699 | 79.347 | 77.52 | 75.81 | 72.961 |
遞延所得稅 | |||||
其他負債,總計 | 1.882 | 2.208 | 2.366 | 2.6 | 2.36 |
總權益 | 197.474 | 182.285 | 219.763 | 264.262 | 281.195 |
普通股 | 0.059 | 0.057 | 0.056 | 0.056 | 0.056 |
額外實收資本 | 1050.63 | 991.182 | 981.95 | 974.356 | 949.043 |
留存收益(累計赤字) | -853.103 | -808.94 | -762.237 | -710.058 | -667.565 |
其他權益,總計 | -0.113 | -0.014 | -0.006 | -0.092 | -0.339 |
總負債和股東權益 | 354.199 | 309.943 | 345.678 | 382.481 | 389.614 |
已發行普通股總數 | 59.0894 | 56.8961 | 56.8524 | 56.6124 | 55.7563 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
應收賬款總額,淨額 | 14.541 | 13.831 | 8.117 | 6.224 | 3.328 |
應收賬款 - 貿易,淨額 | 14.541 | 13.831 | 8.117 | 6.224 | 3.328 |
其他流動資産,總計 | 7.415 | ||||
物業/廠房/設備,總計 - 總額 | 6.534 | ||||
累計折舊,總計 | -3.155 | ||||
其他流動負債,總計 | 9.736 | 7.335 | 5.693 | 1.434 | 1.76 |
長期債務 | 104.699 | 79.347 | 77.52 | 75.81 | 72.961 |
總庫存 | 7.762 | 6.178 | 5.487 | 2.917 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -181.119 | -69.612 | -133.996 | -140.729 | -74.064 |
经营活动产生的现金 | -173.428 | -146.003 | -121.98 | -122.75 | -62.056 |
经营活动产生的现金 | 1.672 | 1.158 | 0.69 | 0.834 | 0.442 |
非现金物品 | 25.743 | -79.446 | 17.221 | 12.078 | 10.899 |
营运资金的变化 | -19.724 | 1.897 | -5.895 | 5.067 | 0.667 |
投资活动产生的现金 | 28.029 | -62.159 | 158.531 | -27.97 | -87.148 |
资本支出 | -0.281 | -0.434 | -0.214 | -3.385 | -0.722 |
其他投资现金流量项目,总计 | 28.31 | -61.725 | 158.745 | -24.585 | -86.426 |
融资活动产生的现金 | 213.828 | 166.481 | 2.009 | 163.474 | 164.686 |
股票的发行(报废),净额 | 141.49 | 166.481 | 2.009 | 163.474 | 164.686 |
现金净变化 | 68.429 | -41.681 | 38.56 | 12.754 | 15.482 |
债务的发行(退还),净额 | 72.338 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -52.179 | -181.119 | -138.626 | -97.765 | -52.764 |
Cash From Operating Activities | -36.433 | -173.428 | -139.428 | -92.441 | -53.632 |
Cash From Operating Activities | 0.457 | 1.672 | 1.23 | 0.788 | 0.35 |
Deferred Taxes | 0 | 0 | 0 | ||
Non-Cash Items | 14.876 | 25.743 | 17.576 | 9.664 | 4.546 |
Changes in Working Capital | 0.413 | -19.724 | -19.608 | -5.128 | -5.764 |
Cash From Investing Activities | 18.464 | 28.029 | 68.804 | 108.501 | 72.522 |
Capital Expenditures | -0.047 | -0.281 | -0.282 | -0.187 | -0.127 |
Other Investing Cash Flow Items, Total | 18.511 | 28.31 | 69.086 | 108.688 | 72.649 |
Cash From Financing Activities | -0.133 | 213.828 | 196.463 | 37.899 | 0.399 |
Issuance (Retirement) of Stock, Net | 1.218 | 141.49 | 121.463 | 0.399 | 0.399 |
Net Change in Cash | -18.016 | 68.429 | 125.839 | 53.959 | 19.289 |
Issuance (Retirement) of Debt, Net | -1.351 | 72.338 | 75 | 37.5 | |
Foreign Exchange Effects | 0.086 |
差價合約交易計算器
如果您在特定日期(選取一個日期)開立差價合約交易並在不同日期(選取一個日期)關閉交易,計算您的假設盈虧。
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Rhythm Pharma Company profile
关于 Rhythm Pharma
Rhythm Pharmaceuticals, Inc.是一家处于商业阶段的生物制药公司。 公司专注于开发肥胖症遗传性疾病的治疗方法,这些疾病的特点是早发、严重肥胖和贪得无厌的饥饿感(吞食过多)。 其主要候选产品IMCIVREE(setmelanotide)是一种有效的黑色素皮质激素-4受体(MC4R)。 IMCIVREE是为治疗罕见的肥胖症遗传性疾病而开发的。 它主要针对黑色素皮质素-4受体(MC4R)途径,该途径负责调节体重和饥饿感。 它以MC4R通路为目标,开发治疗罕见的肥胖症遗传病的药物,包括原肾上腺皮质素(POMC)缺乏症肥胖症、瘦素受体(LEPR)缺乏症肥胖症、Bardet-Biedl综合症(BBS)。 Alstrom综合征,POMC或LEPR杂合体缺乏性肥胖,Smith-Magenis综合征,类固醇受体辅助因子1(SRC1)缺乏性肥胖,MC4R缺乏性肥胖和SH2B适配器蛋白1(SH2B1)缺乏性肥胖。
Industry: | Bio Therapeutic Drugs |
222 Berkeley Street
12th Floor Boston
BOSTON
MASSACHUSETTS 02116
US
收入報表
- Annual
- Quarterly
人們也觀看
还在找一位您可以信任的经纪商吗?
加入成为全球610,000万多名交易者的一份子,选择利用Capital.com进行交易吧。